-
1
Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherap...
Published 2024-01-01Subjects: “…angiogenesis inhibitor…”
Get full text
Article -
2
Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
Published 2025-02-01Subjects: Get full text
Article